Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0014070 (encephalomyelitis)
 13,017 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In experimental autoimmune encephalomyelitis (EAE) induced with myelin proteolipid protein (PLP) peptide 139-151, we have previously shown that the disease is mediated by Th1 cells, which recognize tryptophan 144 as the primary TCR contact point. Here we describe an altered peptide ligand (APL), generated by a single amino acid substitution (tryptophan to glutamine) at position 144 (Q144), which inhibits the development of EAE induced with the native PLP 139-151 peptide (W144). We show that the APL induces T cells that are cross-reactive with the native peptide and that these cells produce Th2 (IL-4 and IL-10) and Th0 (IFN gamma and IL-10) cytokines. Adoptive transfer of T cell lines generated with the APL confer protection from EAE. These data show that changing a single amino acid in an antigenic peptide can significantly influence T cell differentiation and suggest that immune deviation may be one of the mechanisms by which APLs can inhibit an autoimmune disease.
 ...
PMID:An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. 758 31

Experimental autoimmune encephalomyelitis was induced in SJL/J mice by adoptive transfer of a MBP exon-2 peptide-specific T cell line. The T cell line, when tested for antigen specificity, reacted strongly with exon-2 peptide, but not with MBP peptides pAc1-11, p43-88, p89-101 or PLP p139-151. The specificity of splenic or lymph node T cells isolated from mice with acute or first relapse EAE induced by adoptive transfer of the exon-2-specific T cell line was identical to the transferred line. Splenocytes or lymphocytes isolated from mice at the second relapse were reactive with MBP p43-88, p89-101 and PLP p139-151 in addition to exon-2 peptide and MBP peptide Ac1-11. T cell lines selected by culture with MBP exon-2 peptide or PLP p139-151 from splenic cells from mice with relapsing EAE were weakly encephalitogenic; however, T cell lines selected from the same mice with MBP pAc1-11 were not encephalitogenic. T cells from the exon-2 and p139-151 T cell lines primed recipients for rapid onset severe EAE, whereas the pAc1-11 T cell line did not. T cells from the exon-2-specific line did not express V beta 17a+ TCR; however, peptide-specific T cell lines derived from the spleens of relapsing animals did express this TCR gene segment providing direct evidence of recruitment and sensitization of recipient T cells.
 ...
PMID:The immune response to a subdominant epitope in myelin basic protein exon-2 results in immunity to intra- and intermolecular dominant epitopes. 759 53

A high proportion of peptide 1-11 specific T cells from H-2u (V beta 8+, H-2u) mice express the V beta 8 TCR chain. Peptide 89-101 is immunodominant for B10.RIII (V beta 8+, H-2r) mice; thus, it was of interest to determine whether V beta 8 TCR would be over-represented in a population of peptide 89-101-specific T cells of this strain. Second, it was asked whether MBP peptides other than 89-101 would induce EAE in these mice. Of 70 B10.RIII(71NS)/SnJ mice immunized with mouse myelin basic protein (MBP), 32 of 41 males (78%) and 11 of 29 females (38%) showed clinical signs of experimental allergic encephalomyelitis (EAE). All mice immunized with peptide 89-101 showed clinical signs. One of six mice immunized with peptide 91-103 showed clinical signs, and 9 of 16 mice, all males, responded with EAE when immunized with peptide 38-88. No clinical EAE was observed in mice immunized with peptide 43-67, 68-88, 55-74, 1-37 or 1-20. A peptide 89-101-specific T cell line was established. At the initial stimulation the line was 29% V beta 8+ versus 21% in normal controls, and the line did not transfer EAE adoptively. After five in vitro stimulations, the percentage of V beta 8+ T cells had increased to 54%, and the line was encephalitogenic. Encephalitogenicity was partially blocked by anti-V beta 8 monoclonal antibody. Thus, over-representation of V beta 8+ TCR by encephalitogenic peptide-specific T cells is not limited to peptide 1-11-specific T cells from H-2u mice.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Epitope specificity and TCR V beta gene utilization in the encephalitogenic response of B10.RIII(71NS)/SnJ mice. 767 20

Acetylated peptide 1-9 from human myelin basic protein induces experimental allergic encephalomyelitis in PL/J mice through I-Au and TCR V beta 8.2. Murine mAb anti-Id directed against murine mAb to myelin basic protein peptide acetyl 1-9 was examined for effects on in vitro and in vivo T cell activities. Certain anti-Id, generated in PL/J mice, inhibited Ag-specific proliferation and IL-2 production and precipitated surface receptors having features of the TCR. The idiotypic features of TCR recognition were demonstrated by showing that binding of anti-Id to the TCR could be blocked by anti-TCR alpha beta and anti-TCR V beta 8.1-8.2 but not by murine Ig or anti-TCR V beta 17a. In addition, the anti-Id did not react with TCR V beta 8.2 transgenically inserted into MRL+/+ mice. One anti-Id was also capable of lessening clinical disease activity in the adoptive passive transfer model of experimental allergic encephalomyelitis in PL/J mice. These results indicate that anti-Id may recognize a cross-reactive Id on T cells, presumably on the TCR, responsive to the same I-Au-restricted encephalitogenic myelin basic protein peptide in PL/J mice. The selective development of anti-Id and their effect on T cell-mediated tissue damage provide a method for applying specific anti-Id antibodies to modify experimental and, possibly, spontaneous diseases of autoimmune demyelination.
 ...
PMID:Specific modulation of T cells and murine experimental allergic encephalomyelitis by monoclonal anti-idiotypic antibodies. 767 32

Superantigens have the ability to stimulate a subset of T cells based upon their expressed TCR beta-chain. It has been demonstrated that the administration of staphylococcal enterotoxin B (SEB) in mice leads to unresponsiveness in V beta 8+ T cells in vivo which are the same T cells that could be stimulated in vitro by this enterotoxin. We present here data on the effect of SEB administration in DBA/2 and (PL/J x SJL)F1 mice on their T cell response to two different T cell determinants, the responses against which are dominated by the use of V beta 8+ T cells. Treatment of mice with SEB not only diminished their primary T cell proliferative response to these determinants, but also was able to effectively reduce the memory T cell response. SEB treatment, however, showed only a modest effect in preventing Ac 1-11-induced experimental autoimmune encephalomyelitis in H-2u mice.
 ...
PMID:SEB induced anergy: modulation of immune response to T cell determinants of myoglobin and myelin basic protein. 768 Oct 87

Using an inducible expression vector in Escherichia coli, we have expressed, purified, and biologically characterized recombinant human myelin basic protein (r-MBP). The recombinant protein binds in cation-exchange chromatography with similar affinity to purified, human MBP, and elutes as a single, 18.5-kDa species as judged by SDS-PAGE. The recombinant protein exhibits similar conformation to native MBP, as demonstrated by ELISA reactivity with a panel of six monoclonal antibodies directed against at least three different epitopes on human MBP. Additionally, recombinant MBP can trigger the proliferation of human T cell clones recognizing MBP, can induce experimental autoimmune encephalomyelitis (EAE) in the SJL mouse, and is capable of suppressing EAE following tolerization via oral administration. Most important, by using a novel method of purification, the recombinant protein preparation contains no detectable proteolytically derived fragments of MBP, a significant advantage over MBP purified from protease-rich central nervous system tissue. Purified recombinant MBP produced in E. coli will be useful as a biological reagent where highly purified protein devoid of degradation products is needed. Relevance to the study of antigen processing, interactions between MHC and the TCR, as well as for the investigation of antigen-driven immune tolerance are discussed.
 ...
PMID:Biological activity of recombinant human myelin basic protein. 768 37

Synthetic peptides corresponding to germline TCR V beta 8.2 sequences overexpressed by Lewis rat encephalitogenic T cells are effective in the prevention and treatment of autoimmune encephalomyelitis (EAE). In evaluating optimal conditions for identifying disease-relevant target V beta genes, we found that the biased expression of V beta 8.2 was most pronounced in the CNS among activated, IL-2 responsive T cells, but was weakly reflected in the cerebrospinal fluid. Evaluation of basic protein reactive T cells from patients with multiple sclerosis revealed biased expression of V beta 5.2 and to a lesser degree, V beta 6.1. Treatment of 11 MS patients with synthetic TCR V beta 5.2 and V beta 6.1 CDR2 peptides boosted the frequency of anti-TCR reactive T cells in a majority of patients, without compromising recall immunity or causing side effects. TCR peptides may be useful in the treatment of human autoimmune diseases, providing that disease-relevant V genes can be identified.
 ...
PMID:T-cell receptor peptide therapy in EAE and MS. 768 33

The encephalitogenic potential of a segment of myelin basic protein in experimental autoimmune encephalomyelitis is not always mirrored by the ability of the peptide to mediate in vitro activation of encephalitogenic T cells. Recent studies from our laboratory have demonstrated that the responsiveness of Ag-specific T cells in experimental autoimmune encephalomyelitis is determined not exclusively by Ag but also by the nature of the APC. By varying APC during the in vitro selection of T cells, we could generate distinct sets of rat encephalitogenic T cells, as evidenced by the diversity of TCR usage. Here we establish the importance of APC in the activation of rat encephalitogenic T cells by myelin basic protein peptides. Peptides 69-84-Gly and (P80)68-86, which lacked stimulatory activity toward many encephalitogenic T cells in our proliferation assay when standard APC were used, become strongly stimulatory in the presence of less commonly used APC, i.e., an Ia+ T cell clone (LOA) or an Ia-inducible rat glial cell clone (F10). Nonstimulatory APC failed to activate encephalitogenic T cells even when major cytokines were added, suggesting that these cytokines are not among the factors limiting the activating potential of the APC. Thus, whether or not an immunocompetent T cell can be activated by a given Ag in an autoimmune response may be determined by the properties of APC. This finding has implications for current research efforts to identify pathogenic self proteins.
 ...
PMID:Major role of antigen-presenting cells in the response of rat encephalitogenic T cells to myelin basic proteins. 768 28

The biased use of V beta 8.2 and V beta 6 in rats by encephalitogenic T cells specific for the S72-89 and S87-99 epitopes of guinea pig basic protein (Gp-BP) has allowed the use of anti-V beta antibodies and synthetic TCR peptides for treatment of experimental autoimmune encephalomyelitis (EAE). Striking V gene biases also occur in human autoimmune diseases, raising the question of to what degree these biases reflect potentially pathogenic T cells. To address this question, we evaluated the expression of the EAE-associated marker V beta 8.2 and V beta 6 molecules in the periphery, spinal cord (SC), and cerebrospinal fluid (CSF) during the course of EAE, in unselected, IL-2-expanded, and Gp-BP-restimulated populations. In CSF cells, there was a strong bias for the marker V beta before the onset of EAE, but this bias was not enhanced by IL-2, which skewed the CSF population to > 80% CD8+ T cells. In SC, the marker V beta were expressed optimally during the onset of EAE, even in unselected cells, and this bias could be enhanced sequentially by IL-2 expansion and Gp-BP restimulation. During the recovery phase, however, the marker V beta 8.2 bias was obfuscated by the appearance of a heterogeneous V beta T cell population. Biased expression of the marker V genes was not detected in unselected or IL-2-expanded peripheral cells at any time during EAE. These data suggest that peripheral T cells bearing the disease-relevant V genes first appeared in CSF before disease onset and then migrated to SC beginning on the first day of clinical signs. During the recovery phase of the disease, these cells were diluted by an influx of T cells bearing other V beta genes, requiring restimulation with Gp-BP to observe the V beta 8.2 bias. These data have important implications for the interpretation of V beta gene biases that have been reported in human autoimmune diseases.
 ...
PMID:Where, when, and how to detect biased expression of disease-relevant V beta genes in rats with experimental autoimmune encephalomyelitis. 768 48

Staphylococcal enterotoxins (SEs) can bind major histocompatibility antigens and stimulate T cells which bear particular types of T cell receptor. Therefore, it has been postulated that SEs may trigger or modulate the development of autoimmune diseases caused by T cells. In the present study, we examined the effects of SEs on rat encephalitogenic T cells and the clinical manifestation of experimental autoimmune encephalomyelitis (EAE). SED, but not other SEs, stimulated encephalitogenic T cells. Furthermore, culture of lymphoid cells from myelin basic protein (MBP)-immunized rats with SED augmented the clinical manifestation of passively transferred EAE, whereas SEA and SEB showed no significant EAE-transfer ability. Flow cytometric analysis demonstrated that in vitro SED stimulation of T cells from MBP-immunized rats, but not from normal rats, resulted in selective expansion of V beta 8.2+ T cells. Consistent with in vitro findings, in vivo administration of SED modulated EAE elicited by immunization with MBP. SED given after the immunization augmented clinical manifestation, especially at low doses. On the other hand, SED given 7 days before the immunization suppressed the development of EAE in a dose-dependent manner. Interestingly, the same toxin given at a dose of 20 micrograms to thymectomized rats induced enhanced EAE regardless of the timing of administration. It has already been established that SEs stimulate T cells bearing a particular type of TCR V beta chain and subsequently induce unresponsiveness of these T cells. The present results suggest that a similar mechanism may operate in rats after the toxin treatment and MBP immunization. However, in vitro assay showed that the proliferative responses of T cells from EAE-suppressed rats to MBP and SED were not eliminated, suggesting that SED-induced suppressor T cells may also play some roles in EAE suppression. The present study has shown that SED, one of the superantigens, modulates an autoimmune disease. More importantly, its effects are not uniform, but instead are closely related to the dose of the toxin, timing of toxin exposure, and the status of hosts.
 ...
PMID:Immunomodulation of experimental autoimmune encephalomyelitis by staphylococcal enterotoxin D. 768 98


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>